Hydra Biotaparinux for the treatment of pulmonary embolism and secondary prevention of venous thromboembolism events

摘要

The invention relates to idrabiotaparinux for use in the treatment of pulmonary embolism in patients with or without deep venous thrombosis and for the secondary prevention of venous thromboembolic events in said patients, wherein the efficacy and safety of said uses are clinically proven by a phase III clinical trial.